[go: up one dir, main page]

PL2467153T3 - Zastosowanie mimotopów epitopów alfa-synukleiny do leczenia chorób z ciałami Lewy'ego - Google Patents

Zastosowanie mimotopów epitopów alfa-synukleiny do leczenia chorób z ciałami Lewy'ego

Info

Publication number
PL2467153T3
PL2467153T3 PL10747562.6T PL10747562T PL2467153T3 PL 2467153 T3 PL2467153 T3 PL 2467153T3 PL 10747562 T PL10747562 T PL 10747562T PL 2467153 T3 PL2467153 T3 PL 2467153T3
Authority
PL
Poland
Prior art keywords
mimotopes
alpha
lewy body
body diseases
treating lewy
Prior art date
Application number
PL10747562.6T
Other languages
English (en)
Inventor
Markus Mandler
Harald Weninger
Radmila Santic
Christian Lahsnig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2467153T3 publication Critical patent/PL2467153T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL10747562.6T 2009-08-21 2010-08-20 Zastosowanie mimotopów epitopów alfa-synukleiny do leczenia chorób z ciałami Lewy'ego PL2467153T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0132409A AT508638B1 (de) 2009-08-21 2009-08-21 Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien

Publications (1)

Publication Number Publication Date
PL2467153T3 true PL2467153T3 (pl) 2016-09-30

Family

ID=42940852

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10747562.6T PL2467153T3 (pl) 2009-08-21 2010-08-20 Zastosowanie mimotopów epitopów alfa-synukleiny do leczenia chorób z ciałami Lewy'ego

Country Status (22)

Country Link
US (1) US8828942B2 (pl)
EP (1) EP2467153B1 (pl)
JP (2) JP2013502379A (pl)
KR (2) KR101517447B1 (pl)
CN (1) CN102596224B (pl)
AT (1) AT508638B1 (pl)
AU (1) AU2010283948B2 (pl)
BR (1) BR112012003800A2 (pl)
CA (1) CA2771429A1 (pl)
CY (1) CY1117582T1 (pl)
DK (1) DK2467153T3 (pl)
ES (1) ES2573662T3 (pl)
HK (1) HK1170658A1 (pl)
HR (1) HRP20160594T1 (pl)
HU (1) HUE027563T2 (pl)
IL (1) IL218207A0 (pl)
MX (1) MX2012002153A (pl)
PL (1) PL2467153T3 (pl)
PT (1) PT2467153E (pl)
RU (1) RU2532351C2 (pl)
SI (1) SI2467153T1 (pl)
WO (1) WO2011020133A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2579042T3 (da) 2011-10-04 2014-07-21 Affiris Ag Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
WO2015075011A1 (en) 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
CA3003943A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
KR101726549B1 (ko) 2016-06-29 2017-04-12 정상문 모바일 실시간 시뮬레이션 게임에서의 터치 조작 방식
KR102087494B1 (ko) 2018-03-15 2020-03-10 정상문 모바일 실시간 시뮬레이션 게임에서 객체를 표시하는 방법
AU2019406749A1 (en) 2018-12-20 2021-05-27 Saiba AG Virus-like particles of CMV modified by fusion
US20230242601A1 (en) 2020-07-29 2023-08-03 Tohoku University Peptide used to prevent or treat synucleinopathy
IL300364A (en) 2020-08-04 2023-04-01 Ac Immune Sa immunogenic substances
BR112023020640A2 (pt) 2021-04-12 2023-12-05 Saiba AG Partículas similares a vírus de bacteriófago ap205 modificadas
EP4357354A1 (en) * 2021-06-18 2024-04-24 Sumitomo Pharma Co., Ltd. Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide
EP4475878A1 (en) 2022-02-09 2024-12-18 AC Immune SA Anti-alpha-synuclein therapeutic vaccines
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
EP4486388A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate consisting of or comprising at least a ss-glucan or a mannan

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007325595A (ja) * 2000-12-22 2007-12-20 Locomogene Inc 滑膜細胞タンパク質
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
JP4820291B2 (ja) 2003-05-19 2011-11-24 エラン ファーマシューティカルズ，インコーポレイテッド レヴィー小体病におけるαシヌクレインの切断断片
JPWO2004113535A1 (ja) 2003-06-22 2007-09-20 早出　広司 凝集抑制作用を有するシヌクレイン変異体
WO2006004066A1 (ja) * 2004-07-02 2006-01-12 Locomogene, Inc. S1-5を含有するタンパク質製剤
MX2007001679A (es) * 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CN101052417A (zh) * 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
ES2407429T3 (es) * 2005-12-12 2013-06-12 Ac Immune S.A. Vacuna terapéurica
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies

Also Published As

Publication number Publication date
BR112012003800A2 (pt) 2016-11-22
EP2467153B1 (en) 2016-03-02
CA2771429A1 (en) 2011-02-24
HK1170658A1 (zh) 2013-03-08
HUE027563T2 (en) 2016-10-28
MX2012002153A (es) 2012-03-14
SI2467153T1 (sl) 2016-07-29
RU2012110582A (ru) 2013-09-27
US20120156234A1 (en) 2012-06-21
KR20120059562A (ko) 2012-06-08
AT508638A1 (de) 2011-03-15
WO2011020133A1 (en) 2011-02-24
KR101517447B1 (ko) 2015-05-28
HRP20160594T1 (hr) 2016-07-29
PT2467153E (pt) 2016-06-08
US8828942B2 (en) 2014-09-09
KR20140141651A (ko) 2014-12-10
ES2573662T3 (es) 2016-06-09
EP2467153A1 (en) 2012-06-27
CN102596224B (zh) 2015-12-09
JP5901714B2 (ja) 2016-04-13
JP2013502379A (ja) 2013-01-24
JP2015038078A (ja) 2015-02-26
CY1117582T1 (el) 2017-04-26
AU2010283948B2 (en) 2015-01-22
IL218207A0 (en) 2012-04-30
DK2467153T3 (en) 2016-06-06
CN102596224A (zh) 2012-07-18
RU2532351C2 (ru) 2014-11-10
AU2010283948A1 (en) 2012-03-29
AT508638B1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
HK1170658A1 (zh) 用於治療 體病的 -突觸核蛋白表位之模擬表位的用途
HRP20181512T1 (hr) Mimotopi od alfa-sinukleina i njihova cjepiva za liječenje neurodegenerativnih poremećaja
IL216509A0 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
EP2425875A4 (en) MASK COVER
HK1217763A1 (zh) 用於治療疾病的方法
EP2427250A4 (en) THERAPEUTIC BODY STRAP
PH12014501685A1 (en) Humanized antibodies that recognize alpha-synuclein
HK1169804A1 (zh) 治療疼痛的方法
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
EP2498796A4 (en) TREATMENT OF HEART DISEASES
GB0902040D0 (en) Composition for treatment of skin
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
PL2735316T3 (pl) Nowe podejścia terapeutyczne do leczenia stanów zapalnych układu nerwowego
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
EP2512484A4 (en) METHODS FOR THE TREATMENT OF SPEECH DISORDERS
HK1178043A1 (en) Vaporiser for applying steam to a part of the human body
GB0905954D0 (en) Treatment of exacerbations of asthma
GB0908666D0 (en) Treatment of proteostatic disease
TWM386004U (en) Improved structure of incense body
TWM372652U (en) Umbrella capable of covering body